Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2013

View Archived Issues

The discovery and characterization of a first-in-class agent against tuberculosis

Novel lung cancer vaccine CV-9202 evaluated in phase I trial

Phase I study of AG-221 commences in advanced hematological malignancies

The identification of novel genetic mutations in children with epilepsy

New aminoglycoside antibiotic for Gram-negative infections

BTK inhibitors described by Beta Pharma

New antiarrythmics reported by Sanofi

Pfizer discloses novel sodium channel blockers for pain

Successful generation of clinical-grade iPSCs from research-grade cells

The discovery and validation of a topical solution to improve allogeneic corneal graft survival

Sera Prognostics' PAPR study of PreTRM preterm birth test reaches full enrollment

UK DFID supports Drugs for Neglected Diseases initiative

HypoThermosol used in two Intercytex trials of cell-based wound care

Preclinical toxicology study of intravenous PG-545 completed

FDA accepts Pennsaid 2% NDA for review

Sobi seeks European approval for Orfadin oral suspension

Plethora and Shionogi expand agreement for PSD-502

Chugai Pharmaceutical seeks additional formulation approval for Cellcept

Galapagos divulges new series of tyrosine-protein kinase inhibitors

Astellas launches Astagraf XL in U.S. for prophylaxis of organ rejection after kidney transplant

Boehringer Ingelheim to launch Gilotrif tablets in the U.S. in early September

Shire and Santaris extend partnership to develop drugs for rare genetic diseases

C3 Jian completes phase I trial of therapeutic for prevention of tooth decay

EnteraGam launched for the dietary management of IBS-D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...